Article info

Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial

Authors

  1. Correspondence to Dr Jing He, Department of Rheumatology and Immunology, Peking University People's Hospital Beijing China, Beijing 100044, China; hejing1105{at}126.com; Professor Di Yu, Department of Immunology and Infectious Disease, John Curtin School of Medical Research, Australian National University, Canberra, Australia; di.yu{at}anu.edu.au; Dr Xiaolin Sun, Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China; sunxiaolin_sxl{at}126.com; Professor Zhanguo Li, Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China; li99{at}bjmu.edu.cn
View Full Text

Citation

He J, Zhang R, Shao M, et al
Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial

Publication history

  • Received March 17, 2019
  • Revised August 3, 2019
  • Accepted August 6, 2019
  • First published September 19, 2019.
Online issue publication 
December 16, 2019

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.